We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01754025
Recruitment Status : Recruiting
First Posted : December 21, 2012
Last Update Posted : November 20, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:

Lung cancer is a common malignancy that is associated with cigarette smoking but can also affect individuals who never smoked. It is not well understood whether there are hereditary risk factors that influence the risk of lung cancer.

It has been recently found that a small number of families have an inherited (passed from parent to child) change in one of their genes that may contribute to an increased tendency to develop lung cancers, even in never smokers. In some lung cancer patients this gene, called "EGFR", contains a DNA change known as an "inherited EGFR mutation". Early data indicate that these inherited EGFR mutations may be associated with an increased risk of lung cancer.

So far, only a small number of families have been found to carry inherited EGFR mutations. For this reason the risk of lung cancer associated with inherited EGFR mutations is not well understood. Understanding the risk may help investigators find ways of detecting lung cancer sooner or reducing the risk of developing lung cancer.

It was recently discovered that lung cancer patients who are found to carry one rare EGFR mutation in their cancer cells, called "T790M", have an increased risk of carrying an inherited EGFR mutation in their normal cells as well. This represents a new strategy for finding individuals and families carrying inherited EGFR mutations.

This research study is designed to find cancer patients whose tumors have this EGFR mutation, T790M, to find out if they also have an inherited EGFR mutation. Subjects will not have to undergo a biopsy to participate in this research study. Investigators will collect a saliva specimen from patients with a T790M in their cancer to find out if they also have an inherited EGFR mutation.

Study participants found or known to carry an inherited EGFR mutation will have the option of offering their close relative the opportunity to also participate in this study. Close relatives can consider testing to see if they also carry the inherited mutation in their normal cells. Once investigators have identified individuals and relatives that carry inherited EGFR mutations in their genes, investigators will then try to understand the risk of lung cancer and other cancers. Individuals with inherited EGFR mutations will also have the opportunity to participate in future studies related to cancer and other diseases.

This study is being funded in part by the Conquer Cancer Foundation of ASCO and the Bonnie J. Addario Lung Cancer Foundation.

Condition or disease
Lung Cancer

Detailed Description:

If a subject have lung cancer or another cancer carrying a T790M mutation in the EGFR gene, he/she may be eligible to participate in this research study. To determine eligibility, a subject will need to perform the following steps: provide informed consent, fill out the study questionnaire and provide medical records documentation.

The study questionnaire should take about 30 minutes to complete. The questionnaire asks for information on personal and family cancer and health history. The information provided will help investigators to determine which parts of the study a subject is eligible for. A few weeks after submitting the questionnaire, a member of the research study team will contact the subject by telephone to clarify any questions about the response.

For medical records documentation investigators will request permission to obtain and review medical records pertaining to any personal history of cancer. Subjects will need to complete a medical record release form to allow investigators to collect medical records regarding prior cancers and cancer treatment.

After a subject is determined to be eligible, he/she will have a conversation with a genetic counselor regarding the potential risks, benefits and limitations of genetic testing. A genetic counselor is an expert in the field of inherited disorders. They work as members of the health care team and act as a patient advocate providing education and support to the patient, family and the medical team. If a subject agrees to proceed, he/she will be provided a kit (by mail or in person) to provide a saliva sample for genetic testing. This involves spitting into a special container provided by the study. This sample will be sent to a clinically-certified testing laboratory to determine presence of an inherited EGFR mutation.

Once the results have been determined, the subject will receive a letter with the phone number of a genetic counselor to call in order to review results of the genetic testing. Alternatively, a subject can decide not to receive the results of the genetic testing and can note that on the letter received and send it back to the study team instead of calling for the results.

If a mutation is found in the saliva sample, a subject will receive information about how to undergo confirmatory testing of a blood specimen. This can be done at a local laboratory using a kit that will be mailed. When the results are available a genetic counselor will call to discuss them. If the confirmatory blood test confirms an inherited mutation, subjects will receive instructions on how to invite family members to be tested if appropriate.

Investigators will collect material from a prior tumor biopsy (if available), copies of imaging scans, and medical records to study. The copies of imaging scans will allow study of the characteristics of nodules in the lungs. This information will be used to answer additional questions about cancers carrying EGFR T790M mutations.

It will only take a few months to complete the main part of the study. After that, subjects will be followed every 6 months for 2 years. If a subject allows a piece of a tumor specimen or DNA to be stored for future investigational studies, then he/she will remain enrolled in research for as long as the specimen is stored in the specimen bank.

Study Design

Study Type : Observational [Patient Registry]
Estimated Enrollment : 100 participants
Observational Model: Family-Based
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Study Start Date : December 2012
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Groups and Cohorts

Cancer patients with T790M
Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (>40% allelic fraction) EGFR T790M.
Relatives of Carriers
Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
Individuals known to be carriers
Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)

Outcome Measures

Primary Outcome Measures :
  1. Prevalence of EGFR mutations [ Time Frame: 2 years ]
    To determine the prevalence of germline EGFR mutations in lung cancer patients with EGFR T790M mutations in their tumor and in relatives of carriers of germline EGFR mutations

Secondary Outcome Measures :
  1. Preliminary Assessment of History of Lung Cancers [ Time Frame: 2 years ]
    To make a preliminary assessment of the natural history of lung cancers occurring in patients with germline EGFR mutations

  2. Estimate of Prevalence of Lung Nodules [ Time Frame: 2 years ]
    To generate an initial estimate of the prevalence of CT-detected lung nodules in individuals with germline EGFR mutations

Biospecimen Retention:   Samples With DNA
tumor tissue

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects will be identified through participating cancer centers as well as a study website (www.dana-farber.org/T790Mstudy)

Inclusion Criteria:

  • Diagnosis of cancer of any type with an EGFR T790M mutation identified on genotyping of cancer or quantitative plasma genotyping with evidence of high level EGFR T790M; or
  • Have a first- or second-degree relative known to carry a germline EGFR mutation; or
  • Have a known germline EGFR mutation

Exclusion Criteria:

  • Subjects with lung cancer and an acquired T790M mutation first detected after exposure to an EGFR tyrosine kinase inhibitor such as erlotinib or gefitinib
  • Too ill to complete the study questionnaire or provide the necessary specimen for testing
  • Unable to give informed consent
  • Unable to speak or read English
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01754025

Contact: Geoffrey Oxnard, MD 6176326049 goxnard@partners.org
Contact: Ruthia Chen Ruthia_Chen@dfci.harvard.edu

United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Geoffrey Oxnard, MD    617-632-6049    goxnard@partners.org   
Principal Investigator: Geoffrey Oxnard, MD         
United States, Ohio
Ohio State University Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Kate Shane         
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Georgia Wiesner, MD         
Principal Investigator: Georgia Wiesner, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Addario Lung Cancer Medical Institute
Principal Investigator: Geoffrey Oxnard, MD Dana-Farber Cancer Institute
More Information

Additional Information:
Responsible Party: Geoffrey Oxnard, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01754025     History of Changes
Other Study ID Numbers: 12-360
First Posted: December 21, 2012    Key Record Dates
Last Update Posted: November 20, 2017
Last Verified: November 2017

Keywords provided by Geoffrey Oxnard, MD, Dana-Farber Cancer Institute:
Gene Mutation